Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience

Antiviral Research

Volumn 134, Issue , 2016, Pages 58-62

  El Haddad, Danielle ^a   El Chaer, Firas ^a,b   Vanichanan, Jackapat ^a   Shah, Dimpy P ^a   Ariza Heredia, Ella J ^a   Mulanovich, Victor E ^a   Gulbis, Alison M ^a   Shpall, Elizabeth J ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Brincidofovir; Cancer; Cytomegalovirus; Herpes simplex virus; Resistance

Indexed keywords

ACICLOVIR; BRINCIDOFOVIR; CIDOFOVIR; CORTICOSTEROID; FOSCARNET; GANCICLOVIR; IMIQUIMOD; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; NEW DRUG; VALACICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER PATIENT; CASE REPORT; COLITIS; COLON BIOPSY; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; LOOSE FECES; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SEPTIC SHOCK; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CLINICAL TRIAL (TOPIC); COMPLICATION; CYTOMEGALOVIRUS; DRUG EFFECTS; GENETICS; HERPES VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; NEOPLASM; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DRUG RESISTANCE, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPHOSPHONATES;

EID: 84986328593     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.08.024     Document Type: Article

References (12)

1. Beadle, J.R., Hartline, C., Aldern, K.A., et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46 (2002), 2381–2386.
2. Boeckh, M., Ljungman, P., How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113 (2009), 5711–5719.
3. Chimerix Press Release, Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir. 2015 http://ir.chimerix.com/releasedetail.cfm?releaseid=948172 (accessed 01.04.16).
4. Erice, A., Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12 (1999), 286–297.
5. Florescu, D.F., Keck, M.A., Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev. Anti Infect. Ther. 12 (2014), 1171–1178.
6. Gilbert, C., Boivin, G., Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49 (2005), 873–883.
7. Hostetler, K.Y., Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antivir. Res. 82 (2009), A84–A98.
8. Levin, M.J., Bacon, T.H., Leary, J.J., Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin. Infect. Dis. 39:Suppl. 5 (2004), S248–S257.
9. Marty, F.M., Winston, D.J., Rowley, S.D., et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 369 (2013), 1227–1236.
10. Papanicolau, G.K.J., Westervelt, P., Gea-Banacloche, J., Warlick, E., Lanier, R., Anderson, M., Painter, W., Experience with CMX001, a novel antiviral drug, for cytomegalovirus infections in stem cell transplant patients. Biol. Blood Marrow Transplant., 2011, S273–S274.
11. Quenelle, D.C., Lampert, B., Collins, D.J., Rice, T.L., Painter, G.R., Kern, E.R., Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J. Infect. Dis. 202 (2010), 1492–1499.
12. Williams-Aziz, S.L., Hartline, C.B., Harden, E.A., et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49 (2005), 3724–3733.